NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage
biopharmaceutical company with a portfolio of innovative,
late‑stage product candidates targeting neurological diseases,
including rare disorders, today announced that it has commenced an
underwritten public offering of 3,000,000 of its common shares. All
of the common shares to be sold in the offering will be offered by
Biohaven. In addition, Biohaven expects to grant the
underwriters a 30-day option to purchase up to an additional
450,000 common shares at the public offering price, less
underwriting discounts and commissions. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering.
Goldman Sachs & Co. LLC and Piper
Jaffray & Co. are acting as joint book-running managers
of the offering.
The offering is being made only by means of a prospectus.
When available, copies of the prospectus related to the offering
may be obtained from the offices of Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526,
facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com; or from Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at
(800) 747-3924, or by email at prospectus@pjc.com.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission but has not yet
become effective. The securities may not be sold nor may offers to
buy be accepted prior to the time the registration statement
becomes effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy any of these
securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such an offer, solicitation or sale
would be unlawful prior to registration or qualification under the
applicable securities laws of such state or jurisdiction.
Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-proposed-public-offering-of-common-shares-300763005.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.